|
|
George L. Bakris, MD, FAHA, FASN, is Professor of Medicine at the
University of Chicago School of Medicine in Illinois, and serves as Director of the
Hypertension Center in the Diabetes Institute.
Professor Bakris received his medical degree from the Chicago Medical School.
He completed his residency in Internal Medicine at the Mayo Graduate School
of Medicine, where he also completed a research fellowship in Physiology and
Biophysics. He then completed fellowships in Nephrology and Clinical
Pharmacology at the University of Chicago.
|
Professor Bakris specializes in the diagnosis and reduction of high
blood pressure, particularly in complicated or refractory cases. He is also
skilled in the treatment of kidney disease, with special expertise in
diabetes-related kidney disease. Professor Bakris has published over 400
articles and book chapters in the areas of kidney disease, hypertension and
progression of nephropathy. He is the Editor or Co-Editor of several books, all
dealing with Kidney Diseases, Diabetes and the role of Hypertension. Click here for his publications listed with PubMed.
|
|
|
Mihai Gheorghiade,
MD, FACC, FCCP, FACP
Dr. Gheorghiade
currently
serves as Professor of Medicine
and Surgery,
Director of Experimental
Therapeutics
at the Center for
Cardiovascular
Innovation,
Division
of Cardiology,
at Northwestern University’s
Feinberg
School of Medicine
and Northwestern Memorial
Hospital.
|
He
was recently
appointed
Adjunct Professor of Medicine
and Co-Director
of the new
Cardiovascular
Center for
Drug Development
at Duke University.
He graduated
Magna Cum Laude from
the University
of
Rome Medical
School in 1972 and did
his
residency
and fellowship
in cardiology
at Brown University.
He then
moved
to Virginia, where
he
was Chief
of Cardiology
at the Salem
VA Medical
Center and Associate
Professor of Medicine
at the University
of Virginia. In 1985, Dr. Gheorghiade
became
Chief
of the Cardiac
Care Unit at the Henry Ford Hospital
in Detroit and Associate
Professor of Clinical
Medicine
at the University
of Michigan.
During
his
tenures
in Virginia and Michigan,
he
received
numerous
teaching awards
from
both
medical
students
and residents.
In 1992, he
joined
Northwestern University
as Associate
Chief
of the Division
of Cardiology,
Chief
of the Cardiology
Clinical
Service, and Director of the Telemetry
Unit at Northwestern University
Feinberg
School of Medicine
until
2010
Dr. Gheorghiade has served
as a visiting
professor in the United States
and abroad.
He has chaired
or
co-chaired
more than
200 national
and international meetings and has given more than 500 invited
lectures.
He has served
or
is currently
serving
on
the editorial
board of several
journals
including
The American Heart
Journal, The American Journal of Cardiology, Journal of the American
College of Cardiology,
and Circulation
Heart
Failure
Journal, and is an
associated
editor
of the Journal of Cardiovascular
Medicine.
He has also
served
as guest
editor
on
several
occasions for
The American Journal of Cardiology,
The American Heart
Journal, and The American Journal of Medicine. He has chaired many
international trials in heart
failure
including
OPTIME-HF, ACTIV-HF, IMPACT, PRESERVD, HORIZON and COMPOSE
Trials. He also
co-chaired
the global
EVEREST Trial and the ECLIPSE Trial, and was a member of the Steering
Committee
of RADIANCE, FIRST, CARS, RITZ 4, and EPHESUS Trial. In addition, Dr. Gheorghiade
was an
active
member
of the Steering Committee
in the OPTIMIZE-HF
and IMPACT-HF registries. He
currently
serves as Chair
of the international ASTRONAUT, RENO-DEFEND, and IMPROVE-HF Bridge.
Dr. Gheorghiade
has authored
more than
500 peer-reviewed
publications
and more than
300 abstract presentations
at national
and international meetings. He is the co-editor for
two
comprehensive
textbooks
on
acute heart
failure
syndromes
and has written
several
chapters
in many
textbooks
including
Kelley’s
Textbook
of Internal
Medicine,
and Heart
Failure:
A Companion
to Braunwald’s
Heart
Disease,
and most recently
authored
the chapter
on
Acute Heart
Failure
Syndromes
in the ninth
edition
of Braunwald’s
Heart
Disease.
In 2004, Dr. Gheorghiade
founded
the Acute Heart
Failure
Syndromes
International Group, comprised
of physicians,
scientists,
clinicians,
and regulatory
and governmental
agencies
from
North
America
and Europe
to advance
the knowledge
and care of patients
with
acute heart
failure
syndromes
through
clinical
research. This
group
has met annually,
producing
several
consensus documents
published
in Circulation,
Journal of the American College of Cardiology, and European Heart
Journal.
In 2011, Dr. Gheorghiade
assembled
The Academic
Research Team in Heart
Failure(ART
–HF) a group
of expert clinicians
and researchers
with
complimentary
expertise to guide
the development
of heart
failure
therapeutics
spanning the spectrum ranging
from
pre-clinical,
phase
I-III, and post marketing studies; to regulatory and guideline
process
and remains
actively
involved
in animal
and human
research for
the development
of novel
compounds
for
acute heart
failure
syndromes.
He dedicates
significant time and energy
to the mentorship
of medical
students,
residents
and junior faculty
as attested
by
their
primary
authorship
of more than
100 peer-reviewed
publications
in recent years.
Improving
outcomes
of hospitalized
patients
with
heart
failure
through
research and education
remains
his
top priorities.
|
|
|
Professor
of Medicine and Cardiology Robert S. Rosenson, MD, PhD, FACC, FAHA, currently resides in Professor Fuster’s Mount Sinai Heart at The Mount
Sinai Medical Center in New York City.
Before
joining Mount Sinai Heart, he was Professor of Medicine and Director of
Lipoprotein Disorders and Clinical Atherosclerosis Research &
Cardiovascular Diseases at the University of Michigan in Ann Arbor.
|
His clinical research has investigated the effects of lipid-lowering
therapies‚ hypoglycemic therapies and antihypertensive agents on inflammation
and thrombogenesis as well as the effects of hyplolipidemic and
antihypertensive agents on blood viscosity and fibrinogen. Previously‚ he was
Professor of Cardiology at Northwestern University Medical School‚ where he
also served as Director of the Preventative Cardiology Center and Director of
the Lipoprotein and Hemorheology Research Facility. He has published over 70
peer-reviewed scientific papers and nearly 70 book chapters in the field. He
also serves as an editor of a number of journals including Atherosclerosis.
Click here for his publications listed with PubMed.
|
He is the author of over 20 book chapters, over 300 peer reviewed publications
and over 500 abstract presented at national and international scientific conferences.
Dr. Sabbah is member of the editorial board of
several peer-reviewed scientific journals and is the Co Editor-in-Chief of the
journal Heart Failure Reviews. Click here
for his publications listed with PubMed.
|
|
|
John
J.P. Kastelein is Professor of Medicine
and chairman of the Department
of Vascular Medicine at
the Academic Medical
Center (AMC) of the University of Amsterdam, where he holds
the Strategic Chair of Genetics of Cardiovascular Disease.
He received
his medical degree in Amsterdam in 1980 where
he subsequently received specialty training in internal medicine. Then, between 1986 and 1988, he was trained in medical genetics, lipidology and molecular biology at the University of
British Columbia, Vancouver under
the guidance of Prof. Dr. M.R. Hayden.
|
Upon his return to the Netherlands, he was awarded a doctorate (Cum Laude) and in 1989 he
founded the Lipid Research Clinic at the Academic Medical Centre in Amsterdam, which
is currently serving as a tertiary referral centre for over 5000 patients each year
and has become part of the department
of Vascular Medicine.
Dr. Kastelein is president
of the Dutch Atherosclerosis Society (DAS) and chairs the National Scientific Committee on Familial
Hypercholesterolemia (EHC). He also
is a member of the Royal Dutch Society for Medicine & Physics, the Council for Basic Science
of the American Heart Association
and the European Atherosclerosis
Society. He also is a board member
of the International Task Force
for CHD Prevention and was recently appointed to the Executive Board of the International Atherosclerosis
Society (IAS).
Professor Kastelein’s current research interests can be
found in the etiology,
diagnosis, prevention and treatment
of hypertriglyceridaemia, hypercholesterolaemia
and low HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular
disease. He has published
over 540 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England
Journal of Medicine, JAMA and Circulation
and has a Hirsch index of 55.
Besides
the scientific programs aimed
at the etiology of atherogenesis,
Dr. Kastelein also serves on
a number of executive and
steering committees of large
intervention studies, including
the IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER, RADIANCE and numerous others of which TNT (2005), RADIANCE 1 (2007), ENHANCE (2008) and
JUPITER (2008) are published in the New England Journal of Medicine,
IDEAL (2006) in JAMA and RADIANCE 2 (2007) in Lancet
|
